Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ863MR)

This product GTTS-WQ863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13879MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ5312MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ12720MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ6619MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ210MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ138MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ5946MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ9026MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW